Current Trends in Antibody-Based Therapeutics

Authors

  • Vidhi Singh Students, Dayalbagh Educational Institute
  • Kanchan Singh Students, Dayalbagh Educational Institute
  • Prabhas Deshmukh

Abstract

Antibody-based therapeutics have witnessed remarkable advancements in recent years, transforming the landscape of medical treatment. This comprehensive review explores the current trends in antibody-based therapeutics, with a focus on monoclonal antibodies (mAbs), immune checkpoint inhibitors, antibody-drug conjugates (ADCs), bispecific antibodies, and nanobody technology.

How to cite this article:
Deshmukh P, Singh K, Singh V. Current Trends
in Antibody-Based Therapeutics. J Durg Dis Dev
2023; 7(2): 7-11.

Downloads

Published

2023-12-30

How to Cite

Singh, V., Singh, K., & Deshmukh, P. . (2023). Current Trends in Antibody-Based Therapeutics. Journal of Drug Discovery and Development ( ISSN:2581-6861), 7(2), 7-11. Retrieved from http://medicaljournalshouse.com/index.php/JDrug-Discovery-Development/article/view/1082

Issue

Vol. 7 No. 2 (2023): Journal of Drug Discovery and Development

Section

Review Article

License

Copyright (c) 2023 Author's

We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-

1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.

2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.

3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.

4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.

5. I/We also agree to the authorship of the article in the following sequence:-

Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________

Important

(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.

(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.

(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.